Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
Hypera S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | R$3.73 |
52 Week High | R$7.90 |
52 Week Low | R$3.71 |
Beta | 0.40 |
11 Month Change | -25.74% |
3 Month Change | -30.22% |
1 Year Change | -46.00% |
33 Year Change | -29.99% |
5 Year Change | -54.51% |
Change since IPO | -74.30% |
Recent News & Updates
Recent updates
Shareholder Returns
HYPM.Y | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -1.2% | -4.5% | 2.3% |
1Y | -46.0% | 10.9% | 35.1% |
Return vs Industry: HYPM.Y underperformed the US Pharmaceuticals industry which returned 10.9% over the past year.
Return vs Market: HYPM.Y underperformed the US Market which returned 35.1% over the past year.
Price Volatility
HYPM.Y volatility | |
---|---|
HYPM.Y Average Weekly Movement | 7.1% |
Pharmaceuticals Industry Average Movement | 9.4% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: HYPM.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HYPM.Y's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 10,301 | Breno Pires de Oliveira | www.hypera.com.br |
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand.
Hypera S.A. Fundamentals Summary
HYPM.Y fundamental statistics | |
---|---|
Market cap | US$2.45b |
Earnings (TTM) | US$297.45m |
Revenue (TTM) | US$1.41b |
8.0x
P/E Ratio1.7x
P/S RatioIs HYPM.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HYPM.Y income statement (TTM) | |
---|---|
Revenue | R$8.00b |
Cost of Revenue | R$3.05b |
Gross Profit | R$4.95b |
Other Expenses | R$3.26b |
Earnings | R$1.69b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 13, 2024
Earnings per share (EPS) | 2.68 |
Gross Margin | 61.86% |
Net Profit Margin | 21.17% |
Debt/Equity Ratio | 84.8% |
How did HYPM.Y perform over the long term?
See historical performance and comparison